

Technology Appraisal Committee B Interests Register Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer ID3920 Publication Date: 07 February 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Peter Wheatley Price	TAC B Committee Member	Indirect - Financial Interests	Olaparib. Takeda manufacture Leuprorelin (Prostap) a LHRH agonist used in hormone sensitive stages. Previous appraisals at this stage have been declare and participate.	12/09/2023	N/A	It was agreed that Peter's declaration would not prevent him participating in the appraisal committee.
Rhiannon Owen	TAC B Committee Member	Direct - Financial Interests	Paid consultant for AstraZeneca participating in an advisory board for an economic model in metastatic breast cancer which took place on 31st March 2023.	19/09/2023	N/A	It was agreed that Rhiannon's declaration would not prevent her participating in the appraisal committee.
Professor Noel Clarke	Clinical Expert	Direct - Financial interests	Honoraria for national / international lectures relating to prostate and other GU cancers. Honoraria have been received from pharmaceutical companies (Astrazeneca, Bayer, Pfizer, Novartis, Astellas and	04/102023	N/A	It was agreed that Noel's declaration would not prevent him from providing expert advice to the committee.




Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Janssen pharmaceuticals)			
			comprising payment for work			
			done in researching the			
			available scientific data from			
			current and historical trials,			
			preparing slides and themes			
			for presentation and			
			physically travelling to and			
			delivering lectures at			
			National/international			
			symposia addressing the			
			topic of genito-urinary cancer,			
			particularly prostate cancer			
			Honoraria for advisory boards			
			for all major pharmaceutical			
			companies involved in			
			contemporary systemic			
			treatments relating to			
			prostate cancer and prostate			
			cancer trial development.			
			These include Astrazeneca,			
			Bayer, Pfizer, Novartis,			
			Astellas and Janssen			
			pharmaceuticals. This work			
			has been as an independent			
			key opinion leader			
			scrutinising data from current			



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			trials and advising on planning future areas requiring acquisition of trial- based and registration based data on GU cancer			
Professor Noel Clarke	Clinical Expert	Direct - Financial interests	Noel is the joint principal global investigator for the Astrazeneca ProPel Trial of PARP Inhibition in metastatic castrate resistant prostate cancer.	04/102023	N/A	It was agreed that Noel's declaration would not prevent him from providing expert advice to the committee.
Professor Suneil Jain	Clinical Expert	Direct financial interests	Consultancy with Boston Scientific (peri-rectal spacer product for prostate radiotherapy. Advisory Board – Pfizer. PARP inhibitor use in prostate cancer. Advisory Board – Accord healthcare. Hormonal therapy (relugolix) prostate cancer	04/102023	N/A	It was agreed that Suneil's declaration would not prevent him from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Travel and speaker fees – Janssen, Astellas and Bayer			
			Advisory Board – Astra Zeneca – May 2023			
Professor Suneil Jain	Clinical Expert	Direct – non financial	Local-PI of the Amplitude study (Janssen) – evaluating the use of PARP inhibitors in metastatic hormone sensitive prostate cancer. Local-PI and TMG member – the ACE study – a Phase I/II study of a CXCR 1/2 inhibitor in metastatic castrate resistant prostate cancer. Drug was owned and provided by Astra Zeneca. Suneil was local-PI and a member of the trial management group for the TOPARP clinical trial – olaparib in metastatic prostate cancer	04/102023	N/A	



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments